Differentiating Bispecific Administration Between Institutions for Multiple Myeloma
A panel of experts discussed their institutions’ practices for administering bispecific antibodies, BCMA or GPRC5D, to patients with multiple myeloma.
Related Articles
FDA ODAC Votes 5-to-4 Against UGN-102 Intravesical Solution for Bladder Cancer
ODAC has voted against the use of UGN-102 intravesical solution for patients with advanced bladder cancer.
Zanidatamab Displays Safety, Efficacy in HER2-Expressing Gastric Cancer
Antitumor activity was observed in patients with gastroesophageal adenocarcinoma treated with the combination regardless of chemotherapy type.
Cetuximab β/FOLFIRI Prolongs Survival vs FOLFIRI in RAS/BRAF Wild-Type mCRC
For patients with right-sided CRC tumors, no significant progression-free survival difference was observed between the cetuximab and FOLFIRI-only groups.
Leveraging Artificial Intelligence to Bolster Equitable Cancer Care
Authors of a manuscript published in ONCOLOGY® discuss how artificial intelligence may help with cancer detection and improving various patient outcomes.
ZL-1310 Receives FDA Fast Track Designation for Extensive-Stage SCLC
Home to the journal Oncology, Cancer Network provides research and opinion on the screening, early detection, diagnosis, treatment, and prevention of cancers.
3 Things You Should Know About the Multimodal Treatment of SCLC
Here are 3 things you should know about the multimodal treatment of patients with SCLC.
Disitamab Vedotin Combo Extends PFS/OS in HER2+ Urothelial Carcinoma
Treatment with disitamab vedotin and toripalimab improves survival regardless of cisplatin eligibility or HER2 expression level in the phase 3 RC48-C016 trial.
Daratumumab Combo Prolonged Efficacy in Asian Patients with Multiple Myeloma
The safety profile of daratumumab plus bortezomib, melphalan, and prednisone remained stable at follow-up, and no new safety signals were observed.
Phase 3 IDeate-Esophageal01 Trial Initiated for Unresectable ESCC
The trial initiation is based on phase 1/2 IDeate-PanTumor01 trial results presented at the 2022 and 2023 European Society for Medical Oncology Congress.
ADC Innovations With T-DXd/Sacituzumab Govitecan in Breast Cancer
Kit Yu Lu, MD, discusses the applications of T-DXd and sacituzumab govitecan for patients with breast cancer.